North America Sclerotherapy Market By Agent, By Type, By Country, Industry Analysis and Forecast, 2020 - 2026
- October 2020 •
- 48 pages •
- Report ID: 5983201 •
- Format: PDF
Sclerotherapy is a type of minimally invasive procedure that are used for the treatment of or varicose veins. This involves injecting sclerosing agents such as detergents, chemicals, and osmotic agents in the vein. Sclerosing agent cause shrinking of the veins thereby reduces the damage and remove appearance of them. The growing patient geriatric population, technological advancements pertaining to venous diseases, increasing incidence of varicose veins, and rising demand minimally invasive procedures are some of the factors that are driving the market. The introduction of foam sclerotherapy, and ultrasound-guided sclerotherapy has allowed practitioners to adopt these procedures for the painful and underlying veins with accuracy and care. Primary varicose veins are a medical condition in which the congestion occurs in the superficial venous system and may result into eczema and stasis dermatitis.
The attention of both doctors and patients has been shifted towards less-invasive treatment procedures, availability of advanced treatment devices for varicose vein, as well as huge burden of varicose vein cases are the main driving factors in the growth of the market. Other factors include improvement in patient reliability and compliance, increasing healthcare expenditure, and swift growth in aging population.
Though, lack of training for vascular surgeons, expensive treatment procedures for varicose vein, and healthcare reforms in the U.S. and other developed countries are some of the main factors limiting the growth of market. In addition, many challenges are associated with unreliable reimbursement scenario for the varicose vein treatment procedures in the highly competitive market limits the growth of the market.
Based on Agent, the market is segmented into Detergents, Osmotic Agents and Chemical Irritants. Based on Type, the market is segmented into Liquid Sclerotherapy, Ultrasound Sclerotherapy and Foam Sclerotherapy. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Boston Scientific Corporation, Perrigo Company PLC (Omega Pharmaceuticals), Cook Medical, Inc. (Cook Group), Chemische Fabrik Kreussler & Co. GmbH, LGM Pharma, LLC, Troikaa Pharmaceuticals Limited, Tianyu Chang’an Group, Endo-Flex GmbH (Meditek Systems), Merz Pharma GmbH & Co. KGaA, and MTW-Endoskopie W. Haag KG.
Scope of the Study
• Osmotic Agents
• Chemical Irritants
• Liquid Sclerotherapy
• Ultrasound Sclerotherapy
• Foam Sclerotherapy
• Rest of North America
• Boston Scientific Corporation
• Perrigo Company PLC (Omega Pharmaceuticals)
• Cook Medical, Inc. (Cook Group)
• Chemische Fabrik Kreussler & Co. GmbH
• LGM Pharma, LLC
• Troikaa Pharmaceuticals Limited
• Tianyu Chang’an Group
• Endo-Flex GmbH (Meditek Systems)
• Merz Pharma GmbH & Co. KGaA
• MTW-Endoskopie W. Haag KG
• Exhaustive coverage
• Highest number of market tables and figures
• Subscription based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free